NexgenRx Inc. provides administration and adjudication services for health benefit claims in Canada. The company boasts strong financial health with an impressive gross margin of 85.6% and a solid EBITDA margin of 23.2%, indicating efficient operations. However, its market cap of $46.23M and current price of $0.65 suggest potential undervaluation despite healthy margins. Additionally, a low debt-to-equity ratio of 0.03 reflects minimal leverage, which is a strength, but the relatively low return on assets (2.2%) raises concerns about overall asset efficiency.
Loading financial metrics...
No significant red flags identified
This company appears financially healthy on available metrics
Revenue growing at 13.5% YoY, outpacing typical market growth rates.
Operating margin expanded by 7.9pp, demonstrating strong operational leverage.
Both gross margin (+4.4pp) and operating margin (+7.9pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 85.5% indicates strong pricing power and competitive moat.
Gross margin improvement of 4.4pp suggests operational efficiency gains.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Health Information Services companies of a similar size
Based on 2026-Q2 (June 30, 2026)